WESTBOROUGH, Mass. — Miach Orthopaedics has named Jamal Rushdy its next president and CEO as the company prepares for its next stage of growth in the market for anterior cruciate ligament tear treatment.
Rushdy will succeed Patrick McBrayer, who is stepping down following a planned leadership transition conducted with the company’s board of directors. McBrayer will remain president and CEO until Rushdy takes over on May 18.
Miach is the developer of the Bridge-Enhanced ACL Restoration, or BEAR, Implant, a medical device designed to shift ACL tear treatment from reconstruction to restoration.
“Patrick joined Miach at a pivotal moment, as we were accelerating commercialization of the BEAR Implant,” said Joyce Erony, chairwoman of the Miach board and managing partner at Amzak Health. “Under his leadership, the company has established a strong presence in ACL restoration, with the BEAR Implant now used by more than 750 surgeons and to treat over 9,000 patients. Jamal is the right person to build on that foundation and guide Miach through its next phase of growth.”
Rushdy has nearly 30 years of experience in the medical device industry, including work in orthopedics, sports medicine and regenerative medicine. He most recently served as CEO of Arcuro Medical and previously led Collagen Solutions. He has also held senior leadership roles at Tornier and DJO, now Enovis, and was a founding executive of three medtech companies with multiple successful exits.
“Miach has built strong momentum with differentiated technology and compelling clinical evidence behind the BEAR Implant,” Rushdy said. “The opportunity now is to expand use and advance new indications, with the goal of helping people with ACL tears return to an active lifestyle while preserving long-term knee health. I’m excited to work with the Miach team and the orthopedic community to bring the benefits of the BEAR Implant to even more people, and I thank Patrick for his support.”
The BEAR Implant is described by the company as the first disruptive technology in ACL tear treatment in more than 30 years. Unlike traditional ACL reconstruction, which replaces the ACL with a graft, the implant is designed to help a torn ACL heal and restore the knee’s natural function.
McBrayer joined Miach in 2022 and helped lead the company through a period of commercialization and growth. During his tenure, Miach secured more than $60 million in funding, expanded adoption of the BEAR Implant and received FDA approval for label updates allowing use in children and adolescents of any age and for partial ACL tears. The updates also included reduced risk of developing radiographically confirmed post-traumatic osteoarthritis.
“Miach is entering its next chapter with strong momentum, and it has been an honor to lead the company’s efforts to transform the treatment of ACL tears over the past several years,” McBrayer said. “What this team has accomplished, from bringing the BEAR Implant into broader clinical use to expanding its adoption among surgeons, has been incredibly meaningful. I’m beyond proud of what this team has built and excited about the impact Miach will continue to have in the years ahead.”
